There is evidence that adenosine and morphine interact in the striatum. How
ever, little is known about the precise role of the opioid receptor subtype
s implicated in the modulation of adenosine tissue concentration and in ade
nosine receptor expression and function. We sought to evaluate, in the abse
nce of withdrawal symptoms, the effects of the short-term administration of
selective mu-, delta- or kappa-opioid receptor agonists on adenosine conce
ntration and on adenosine A(2A) receptor function in rat striatum. Adenosin
e A(2A) receptor was chosen because the neuronal sub-population expressing
this receptor coexpresses enkephalin, suggesting that adenosine A(2A) recep
tor may be regulated by opioid receptor agonists. Oxymorphone hydrochloride
(mu-opioid receptor agonist, 6 mg/kg/day), +[-(5 alpha,7 alpha,8 beta)-(-)
-N-methyl-N(7-(1-pyrrolidinyl)1-oxaspiro (4.5)dec-8-yl) benzenacetamide] (U
69593) (kappa-opioid receptor agonist, 0.75 mg/kg/day), and (+)-4[(alpha R)
-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-di
ethylbenzamide) (SNC80) (delta-opioid receptor agonist, 9 mm/kg/day), or ve
hicle, were administered i.p 3 x daily during 5 days to groups of rats (n =
6). We also investigated the effects of opioid receptor agonists on adenos
ine uptake by striatal cell extracts. We found that administration of mu- o
r delta-opioid receptor agonists significantly decreased adenosine uptake i
n striatal cell extracts and increased adenosine concentration (mean +24% a
nd +45% for mu- and delta-opioid receptor agonist, respectively, relative t
o controls). None of the receptor agonists tested induced obvious modificat
ions of adenosine A(2A) receptor function. However, the delta-opioid recept
or agonist induced an increase in adenosine A(2A) mRNA expression (mean 44%
). We conclude that mu and delta receptor agonists inhibit adenosine uptake
by striatal cell extracts and increase adenosine concentrations in rat str
iatum. (C) 2000 Elsevier Science B.V, All rights reserved.